Great Ormond Street Hospital Children's Charity is committed to supporting high quality research with the potential to improve the health and wellbeing of children at Great Ormond Street Hospital (GOSH), through better diagnosis, treatment, improved care and cures. Our niche is the rapid translation of research for patient benefit.
Clinical Research Starter Grants 2014-2015
THIS CALL IS NOW CLOSED.
Scope of call
Great Ormond Street Hospital Children's Charity is inviting clinically focused pilot or feasibility studies with strong potential to benefit patients and have an impact at the point-of-care. Studies should allow investigators to gather preliminary data or samples and/or develop a research question. This is intended to be pump-prime funding that will help investigators gather proof-of-concept data needed to move the research into the next stage. It is expected that applicants will leverage the Great Ormond Street Hospital Children's Charity grant to obtain funding from the NIHR or another external funding body. Lead Applicants must be research-active GOSH health professionals and have a contract or honorary contract with GOSH.
We particularly encourage proposals that:
Are highly translational and likely to benefit patients directly.
Address problems that will have an impact at the point-of-care.
Make the most of the unique patient population at GOSH.
Demonstrate real partnership between clinical and academic researchers. Rapid progress will often need a multidisciplinary approach, or sharing of resources and knowledge.
Up to £500,000 is available to spend under this call and it is anticipated that we will fund a range of proposals from different investigators. Funding will be provided for the direct costs of research (such as research staff and consumables) and will not cover consultant PAs or team-leader salary time. Typically, projects will be between 12–18 months duration.
National call for applications in Translational Paediatric Rare Disease Research 2014-2015
THIS CALL IS NOW CLOSED.
Scope of call
Rare diseases are currently under-researched and under-resourced and they can often leave patients and their families feeling isolated and vulnerable. Rare diseases have a low prevalence but a high level of complexity. For rare syndromes, diagnosis may be difficult and delayed due to limited scientific knowledge and clinical recognition of the disease. 75 per cent of rare diseases affect children. GOSH specialises in the care of children with rare syndrome and hosts 19 nationally commissioned services for such conditions, the largest number in a single NHS Trust. The charity is committed to investment in rare disease research and in addition to this call is developing a new Centre for Research into Rare Disease in Children, a £90 million research facility, due to be completed in 2017.
Research that will improve the diagnosis of rare diseases will be prioritised and for the purposes of this call the definition of a rare disease is one that affects fewer than five in 10,000 people.
We particularly encourage highly translational proposals that:
Address problems that will have an impact at the point-of-care
Are based on practical research that will have an impact on health services and delivery
Have a robust study design and established access to the relevant patient population
Are multidisciplinary in nature and demonstrate real partnership between clinical and academic researchers
Have the potential to leverage Great Ormond Street Hospital Children's Charity funding and lead to a larger grant
Up to £1 million is available to spend under this call and it is anticipated that we will fund a range of proposals from different investigators and institutions. Funding will be provided for the direct costs of research (such as research staff and consumables) and will not cover consultant PAs or team-leader salary time. Typically, projects will be up to three years duration.
Who may apply?
Great Ormond Street Hospital Children's Charity is inviting project grant applications from across the UK that have the potential to impact patients at GOSH and elsewhere.
Previous National Funding Calls
Translational Paediatric Biomarker Research funding call (2013-2014)
We received a total of 38 outline applications in response to the charity’s joint national call for outline proposals in November 2012.
Following a triage meeting held on 10 January 2013, 16 full applications were invited to be submitted in March 2013 for full external peer review.
A National Assessment Panel met on 28 June 2013 to review these applications. Present at the meeting were Professor David Armstrong (Panel Chair), Dr Colin Michie, Professor Tim Barrett, Dr Peter Grabowski and Dr William van’t Hoff, with scores received in advance from Professor Bobby Gaspar.
The following six projects totalling £947,574 were awarded grants:
Table showing the six projects awarded grants for the Translational Paediatric Biomarker funding call in 2012-2013
|Lead investigator ||Host institution ||Total ||Project title |
|Paul Humphries ||University College London ||£100,500 ||Whole body PET-MRI in paediatric and adolescent lymphoma |
|Michael Levin ||Imperial College London ||£260,246 ||A rapid diagnostic test to discriminate bacterial and viral infection in febrile children based on RNA expression signature |
|David Michod ||UCL Institute of Child Health ||£40,500 ||Phosphorylation of the H3.3 chaperone DAXX as a new biomarker and a new target for treatment of high grade gliomas in children |
|David Long ||UCL Institute of Child Health ||£195,526 ||Angiopoietin-2 as a biomarker and mediator of cardiovascular disease in children |
|Vivek Muthurangu ||Institute of Cardiovascular Science ||£184,975 ||Magnetic resonance augmented exercise testing: a novel biomarker in paediatric pulmonary hypertension |
|Kathy Pritchard-Jones ||UCL Institute of Child Health ||£165,827 ||Prognostic value of 1q gain in Wilms' tumour |
CHILDREN with CANCER UK and GOSH Children's Charity joint national funding call for applications in translational paediatric cancer research (2012-2013)
We received a total of 33 outline applications in response to the charity’s joint national call for outline proposals in November 2011.
Following a triage meeting held on 5 December 2011, 15 full applications were invited to be submitted in February 2012 for full external peer review.
A joint research assessment panel met on 15 May 2012 to review these applications. Present at the meeting were Professor David Armstrong (Panel Chair), Dr Nicholas Goulden, Professor Geoff Pilkington, Professor Kathy Pritchard-Jones, Professor Keith Wheatley and Dr William van’t Hoff, with scores received in advance from Professor Faith Gibson and Professor Malcolm Taylor.
The following eight projects totalling £1,572,231 were awarded grants:
Table showing the eight projects awarded grants for the CHILDREN with CANCER UK and GOSH Children's Charity research call 2011-12
|Lead investigator ||Host institution ||Total || Project title |
|John Anderson ||UCL Institute of Child Health ||£302,390 ||Combinatorial targeting of anaplastic lymphoma kinase for neuroblastoma immunotherapy |
|Nicholas Coleman ||University of Cambridge ||£99,840 ||Novel genetic markers for blood-based monitoring of treatment response in common childhood cancers |
|Tariq Enver ||UCL Cancer Institute ||£284,915 ||Feasibility and clinical and scientific value of leukaemic stem cell monitoring during acute lymphoblastic leukaemia therapy |
|Rob Mairs ||University of Glasgow ||£158,857 || |
Assessment of [131I]MIBG in combination with cytotoxic drugs for neuroblastoma therapy
|Juan Pedro Martinez-Barbera ||UCL Institute of Child Health ||£79,152 ||Development of novel chemical therapies against the paediatric form of human craniopharyngioma |
|Vaskar Saha ||University of Manchester ||£281,222 ||Optimisation of the use of L-asparaginase and dexamethasone in childhood acute lymphoblastic leukaemia |
| Janet Shipley ||Institute of Cancer Research || £227,368 ||Preclinical testing of FGFR inhibitors for the treatment of rhabdomyosarcoma |
| Andrew Stocker ||UCL Institute of Child Health || £138,488 ||Combination treatments to drive neuroblastoma tumour differentiation and senescence |